“That's your take. Mine is that I think NASH wil
Post# of 151645
Again, the problem is enrollment. Leronlimab very well could show that type of efficacy but the trial needs to enroll all 90 patients before data can be released. If the trial can be fully enrolled by summer, we could get results by the end of next year. We’ll likely get an update on NASH trial enrollment during an upcoming CC and that’ll give us an idea on speed of enrollment.

